CX02 is a therapeutic candidate currently under development for the treatment of non-alcoholic steatohepatitis (NASH) and related metabolic disorders, functioning as an inhibitor of the enzyme sterol regulatory… Read more








CX02 is a therapeutic candidate currently under development for the treatment of non-alcoholic steatohepatitis (NASH) and related metabolic disorders, functioning as an inhibitor of the enzyme sterol regulatory element-binding protein-1c (SREBP-1c). This category contains essential reference standards for the drug, including a comprehensive selection of degradation products and process-related impurities. These compounds are critical for pharmaceutical laboratories performing impurity profiling, method validation, and stability testing. By utilizing these high-quality standards, researchers can accurately identify and quantify related substances, ensuring rigorous quality control during the characterization of the drug substance. Whether establishing release specifications or conducting forced degradation studies, these materials support the precise analytical testing required throughout the lifecycle of drug development, helping to maintain compliance and safety standards for this therapeutic agent.